Amgen Inc (AMGN)

$366.20 +27.61 (8.15%)
Market Cap 184.10B
Revenue (ttm) 33.42B
Net Income (ttm) 4.09B
EPS (ttm) N/A
PE Ratio 15.68
Forward PE 15.70
Profit Margin 12.24%
Debt to Equity Ratio 5.67
Volume 5,898,500
Avg Vol 2,849,938
Day's Range N/A - N/A
Shares Out 538.48M
Stochastic %K 3%
Beta 0.45
Analysts Sell
Price Target $336.29

Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of my...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 805 447 1000
Fax: 805 447 1010
Address:
One Amgen Center Drive, Thousand Oaks, United States
DefenseMania
DefenseMania Feb. 4 at 11:12 PM
$AMGN for you younglings , why LT investing will make u MILLIONAIRES. .09-.12 cent stock at one point with at least 5 stock spots (forward)
0 · Reply
TalkMarkets
TalkMarkets Feb. 4 at 9:33 PM
#Nasdaq, S&P 500 Settle Lower On Extended #Tech Rotation $AMGN $GLD $OIL $SPX $VIX https://talkmarkets.com/content/commodities/nasdaq-sp-500-settle-lower-on-extended-tech-rotation?post=555046
0 · Reply
topstockalerts
topstockalerts Feb. 4 at 9:17 PM
For the Dow, Amgen was among the names fueling outperformance. The biotechnology stock was higher by 8% after the company reported better-than-expected earnings and revenue for the fourth quarter. Honeywell also offered a boost to the index, rising almost 2% as investors moved from tech into more value-oriented names. “It’s just a natural rotation,” Welch said. “It’s been such a large cap growth-dominated space for so long — value was just punished, small cap was punished and non-U.S. markets were just kind of ignored when, in fact, they basically doubled the results of the domestic market last year.” $DJIA $AMGN
0 · Reply
howardlindzon
howardlindzon Feb. 4 at 8:22 PM
$AMGN market found a new lover
0 · Reply
JFDI
JFDI Feb. 4 at 8:22 PM
no love for $AMGN today? wtf?
0 · Reply
IN0V8
IN0V8 Feb. 4 at 7:21 PM
$AMGN Citigroup raises target price to $345 from $315 Leerink Partners raises target price to $355 from $305 Morgan Stanley raises target price to $309 from $304 RBC raises target price to $360 from $335 TD Cowen raises target price to $420 from $389 TD Cowen cuts target price to $35 from $40
0 · Reply
erevnon
erevnon Feb. 4 at 7:19 PM
Citigroup maintains Amgen $AMGN at Neutral and raises the price target from $315 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
notreload_ai
notreload_ai Feb. 4 at 6:57 PM
$AMGN reports strong Q4 2025 earnings with $9.87B revenue, beating estimates. Company defies FDA request to withdraw Tavneos while advancing obesity drug MariTide through trials. https://notreload.xyz/amgen-beats-q4-expectations-despite-fda-drug-controversy/
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 4 at 6:37 PM
$AMGN Trading in a wide range between around $365 and $262. Volume has been fluctuating but staying above average. Bulls and bears seem to be battling it out around these levels.
0 · Reply
REDBEAR
REDBEAR Feb. 4 at 6:17 PM
$AMGN let's go! We have to catch $CAT $WMT $HON $CVX This b/o is strong. Those others are way overbought or not strong enough
0 · Reply
Latest News on AMGN
Why Amgen Stock Is Paying Off Big For Long-Term Investors

Feb 4, 2026, 10:50 AM EST - 8 hours ago

Why Amgen Stock Is Paying Off Big For Long-Term Investors

Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge

Feb 4, 2026, 7:55 AM EST - 11 hours ago

Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge

Amgen Inc. (AMGN) Q4 2025 Earnings Call Transcript

Feb 3, 2026, 8:20 PM EST - 23 hours ago

Amgen Inc. (AMGN) Q4 2025 Earnings Call Transcript

Amgen Logs Higher Fourth-Quarter Revenue on Double-Digit Volume Boost

Feb 3, 2026, 4:58 PM EST - 1 day ago

Amgen Logs Higher Fourth-Quarter Revenue on Double-Digit Volume Boost

Amgen quarterly results beat Street estimates on higher sales, lower tax rate

Feb 3, 2026, 4:05 PM EST - 1 day ago

Amgen quarterly results beat Street estimates on higher sales, lower tax rate

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

Feb 3, 2026, 4:01 PM EST - 1 day ago

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 1 day ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT GPCR LLY NVO PFE VKTX

Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends

Jan 30, 2026, 1:09 PM EST - 5 days ago

Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends

AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Jan 28, 2026, 4:01 PM EST - 7 days ago

AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Amgen: A Buy In 2026 On Exciting MariTide Obesity - T2D Potential

Jan 22, 2026, 11:15 AM EST - 13 days ago

Amgen: A Buy In 2026 On Exciting MariTide Obesity - T2D Potential

Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access

Jan 20, 2026, 11:34 AM EST - 15 days ago

Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access

Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing

Jan 15, 2026, 4:40 PM EST - 20 days ago

Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing

Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

Jan 14, 2026, 12:36 PM EST - 21 days ago

Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

Amgen CEO Bob Bradway goes one-on-one with Jim Cramer

Jan 13, 2026, 7:55 PM EST - 21 days ago

Amgen CEO Bob Bradway goes one-on-one with Jim Cramer

Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss

Jan 13, 2026, 7:51 PM EST - 21 days ago

Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss

Amgen CEO says weight loss drug can address 'patient persistence issue'

Jan 13, 2026, 6:54 PM EST - 22 days ago

Amgen CEO says weight loss drug can address 'patient persistence issue'

Ro partners with Amgen to study barriers to obesity care, GLP-1 access

Jan 13, 2026, 10:22 AM EST - 22 days ago

Ro partners with Amgen to study barriers to obesity care, GLP-1 access

Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 9:16 PM EST - 22 days ago

Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Amgen says MariTide helped trial patients maintain weight loss

Jan 12, 2026, 7:42 PM EST - 22 days ago

Amgen says MariTide helped trial patients maintain weight loss

Amgen to announce data on obesity drug MariTide at healthcare conference

Jan 12, 2026, 6:46 PM EST - 23 days ago

Amgen to announce data on obesity drug MariTide at healthcare conference

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

Jan 11, 2026, 7:40 AM EST - 24 days ago

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

CVX HD JNJ KO MRK NKE PG

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

Jan 10, 2026, 9:52 AM EST - 25 days ago

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

CRM DIS HD HON JNJ KO MRK

Healthy Returns: What to expect from pharma at the JPM conference

Jan 9, 2026, 12:57 PM EST - 26 days ago

Healthy Returns: What to expect from pharma at the JPM conference

AZN BMY LLY MRK NVO PFE

AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Jan 7, 2026, 4:01 PM EST - 4 weeks ago

AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs

Jan 7, 2026, 1:45 PM EST - 4 weeks ago

Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE

Jan 6, 2026, 9:00 AM EST - 4 weeks ago

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

Jan 2, 2026, 5:06 PM EST - 4 weeks ago

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

CVX HD JNJ KO MRK NKE PG

These three ‘Dogs of the Dow' stocks are must-own for 2026

Dec 31, 2025, 12:12 PM EST - 5 weeks ago

These three ‘Dogs of the Dow' stocks are must-own for 2026

HD VZ

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

Dec 26, 2025, 10:35 PM EST - 5 weeks ago

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

CVX KMB ABM ABT AVGO BCPC BEN

Can Amgen Sustain Its Rally In 2026

Dec 26, 2025, 1:03 PM EST - 5 weeks ago

Can Amgen Sustain Its Rally In 2026

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

Dec 19, 2025, 6:25 PM EST - 6 weeks ago

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

ALNY ARGX AZN IBB

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

Dec 19, 2025, 4:09 PM EST - 6 weeks ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

BMY GSK MRK GILD NVS SNY

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

Dec 19, 2025, 3:14 PM EST - 6 weeks ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

BMY GILD GSK MRK NVS SNY

Nine of the largest pharma companies ink deals with Trump to lower drug prices

Dec 19, 2025, 2:34 PM EST - 6 weeks ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

BMY GILD GSK MRK NVS SNY

AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS

Dec 19, 2025, 2:23 PM EST - 6 weeks ago

AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS

Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 6 weeks ago

Trump to announce new drug-pricing deals later today

ABBV AZN BMY GILD LLY MRK NVO

AbbVie, several other pharma companies near MFN deal with Trump, sources say

Dec 17, 2025, 4:11 PM EST - 7 weeks ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AZN BMY LLY NVS PFE

FDA Approves Amgen's UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease

Dec 12, 2025, 12:43 PM EST - 7 weeks ago

FDA Approves Amgen's UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease

FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS

Dec 11, 2025, 6:09 PM EST - 7 weeks ago

FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS

AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND

Dec 9, 2025, 4:01 PM EST - 2 months ago

AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND

Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 5:23 PM EST - 2 months ago

Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 5:13 PM EST - 2 months ago

Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dogs Of The Dow Continue Outperforming Broader Market

Nov 29, 2025, 1:45 AM EST - 2 months ago

Dogs Of The Dow Continue Outperforming Broader Market

DIA JNJ MAGS SPY

AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE

Nov 24, 2025, 4:10 PM EST - 2 months ago

AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE

AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE

Nov 24, 2025, 4:00 PM EST - 2 months ago

AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

Nov 20, 2025, 11:17 AM EST - 2 months ago

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

BMY GILD IVV MRK PFE SPY VOO

FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER

Nov 19, 2025, 4:01 PM EST - 2 months ago

FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER

Global drugmakers rush to boost US presence as tariff threat looms

Nov 18, 2025, 8:25 AM EST - 2 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AZN BIIB GILD GSK JNJ LLY

Trade Tracker: Bill Baruch buys more Amgen

Nov 13, 2025, 1:54 PM EST - 2 months ago

Trade Tracker: Bill Baruch buys more Amgen

Cramer's Stop Trading: Amgen

Nov 13, 2025, 10:30 AM EST - 2 months ago

Cramer's Stop Trading: Amgen

DefenseMania
DefenseMania Feb. 4 at 11:12 PM
$AMGN for you younglings , why LT investing will make u MILLIONAIRES. .09-.12 cent stock at one point with at least 5 stock spots (forward)
0 · Reply
TalkMarkets
TalkMarkets Feb. 4 at 9:33 PM
#Nasdaq, S&P 500 Settle Lower On Extended #Tech Rotation $AMGN $GLD $OIL $SPX $VIX https://talkmarkets.com/content/commodities/nasdaq-sp-500-settle-lower-on-extended-tech-rotation?post=555046
0 · Reply
topstockalerts
topstockalerts Feb. 4 at 9:17 PM
For the Dow, Amgen was among the names fueling outperformance. The biotechnology stock was higher by 8% after the company reported better-than-expected earnings and revenue for the fourth quarter. Honeywell also offered a boost to the index, rising almost 2% as investors moved from tech into more value-oriented names. “It’s just a natural rotation,” Welch said. “It’s been such a large cap growth-dominated space for so long — value was just punished, small cap was punished and non-U.S. markets were just kind of ignored when, in fact, they basically doubled the results of the domestic market last year.” $DJIA $AMGN
0 · Reply
howardlindzon
howardlindzon Feb. 4 at 8:22 PM
$AMGN market found a new lover
0 · Reply
JFDI
JFDI Feb. 4 at 8:22 PM
no love for $AMGN today? wtf?
0 · Reply
IN0V8
IN0V8 Feb. 4 at 7:21 PM
$AMGN Citigroup raises target price to $345 from $315 Leerink Partners raises target price to $355 from $305 Morgan Stanley raises target price to $309 from $304 RBC raises target price to $360 from $335 TD Cowen raises target price to $420 from $389 TD Cowen cuts target price to $35 from $40
0 · Reply
erevnon
erevnon Feb. 4 at 7:19 PM
Citigroup maintains Amgen $AMGN at Neutral and raises the price target from $315 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
notreload_ai
notreload_ai Feb. 4 at 6:57 PM
$AMGN reports strong Q4 2025 earnings with $9.87B revenue, beating estimates. Company defies FDA request to withdraw Tavneos while advancing obesity drug MariTide through trials. https://notreload.xyz/amgen-beats-q4-expectations-despite-fda-drug-controversy/
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 4 at 6:37 PM
$AMGN Trading in a wide range between around $365 and $262. Volume has been fluctuating but staying above average. Bulls and bears seem to be battling it out around these levels.
0 · Reply
REDBEAR
REDBEAR Feb. 4 at 6:17 PM
$AMGN let's go! We have to catch $CAT $WMT $HON $CVX This b/o is strong. Those others are way overbought or not strong enough
0 · Reply
erevnon
erevnon Feb. 4 at 6:15 PM
Cantor Fitzgerald maintains Amgen $AMGN at Neutral and raises the price target from $315 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
inspector_gadget86
inspector_gadget86 Feb. 4 at 6:04 PM
$AMGN reported better-than-expected earnings and revenue for the fourth quarter
0 · Reply
topstockalerts
topstockalerts Feb. 4 at 5:36 PM
$AMGN Holding firm at these levels. Buyers keep stepping in on dips. This shows real demand.
0 · Reply
judgeyoung2
judgeyoung2 Feb. 4 at 5:34 PM
$AMGN
0 · Reply
ZacksResearch
ZacksResearch Feb. 4 at 4:59 PM
$AMGN just delivered a clean Q4 beat — and now the real catalyst is coming. 👀 Q4 earnings and revenue topped estimates, driven by strong drug volumes, while investor focus shifts to its late-stage MariTide obesity studies — a key storyline going forward. See why Amgen is back in focus and what to watch next 👉 https://www.zacks.com/stock/news/2829051/amgns-q4-earnings-sales-beat-estimates-obesity-candidate-in-focus?cid=sm-stocktwits-2-2829051-teaser-31955&ADID=SYND_STOCKTWITS_TWEET_2_2829051_TEASER_31955
0 · Reply
Jamtrades
Jamtrades Feb. 4 at 4:10 PM
Investors are excited about Maritide, and the company is bullish on it.. $AMGN to $377
0 · Reply
ZacksResearch
ZacksResearch Feb. 4 at 3:59 PM
$AMGN Q4 2025: Strong Results, But What About 2026? 🤔 📈 EPS of $5.29 beats estimates, total revenue up 9% YoY to $9.9B 🔬 R&D costs surge 26% as MariTide development takes center stage 💊 Prolia & Xgeva facing 2026 patent cliffs, impacting future sales Is AMGN positioned to tackle upcoming challenges? Full analysis here 👉 https://www.zacks.com/stock/news/2829051/amgns-q4-earnings-sales-beat-estimates-obesity-candidate-in-focus?cid=sm-stocktwits-2-2829051-body-31956&ADID=SYND_STOCKTWITS_TWEET_2_2829051_BODY_31956
0 · Reply
judgeyoung2
judgeyoung2 Feb. 4 at 3:32 PM
$AMGN breaking out
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 4 at 1:37 PM
$AMGN (+0.6% pre) Amgen Q4 results beat Street estimates, company says patients need weight-loss options https://ooc.bz/l/91915
0 · Reply
mikesterz7
mikesterz7 Feb. 4 at 12:10 PM
$AMGN A broad blockbuster lineup drove 2025 performance, with 14 products generating at least $1B each in annual sales. Its pipeline focuses on cardiometabolic, obesity, and oncology, with Repatha backed by Phase 3 data showing a 25% reduction in first major cardiovascular events.
0 · Reply
StocktwitsNews
StocktwitsNews Feb. 4 at 5:43 AM
Amgen CEO Teases 2026 As ‘Springboard Year’ After 14 Blockbusters And 18 Record Products $AMGN https://stocktwits.com/news/equity/markets/amgen-ceo-teases-2026-as-springboard-year-after-blockbusters-and-record-products/cZbSYcRR4Zb
0 · Reply
TalkMarkets
TalkMarkets Feb. 4 at 5:15 AM
Markets Rotate Back Out Of Tech, Q4 Earnings After The Close $AMD $CMG $ADP $AMGN https://talkmarkets.com/content/stocks--equities/markets-rotate-back-out-of-tech-q4-earnings-after-the-close?post=554794
0 · Reply